Research Article
Comparing the Efficacy and Safety of Induction Therapies for the Treatment of Patients with Proliferative Lupus Nephritis in South Africa
Table 4
Multivariable analysis for the predictors of remission and mortality.
| | Remission | Mortality | Odds ratio (95% CI) | value | Odds ratio (95% CI) | value |
| Age (years) | 1.0 (0.9–1.1) | 0.43 | 1.02 (0.94–1.09) | 0.69 | Gender | Female | 1 | 0.48 | 1 | 0.66 | Male | 2.4 (0.2–28.3) | 0.60 (0.06–5.87) | Ethnicity | Black Africans | 1 | 0.62 | 1 | 0.59 | Mixed ancestry | 1.5 (0.3–6.5) | 0.66 (0.14–3.01) | Induction regimen | IVCYC | 1 | 0.20 | 1 | 0.11 | MMF | 3.2 (0.5–18.0) | 0.07 (0.003–1.87) | Baseline eGFR | 1.0 (0.97–1.0) | 0.43 | 0.95 (0.92–0.98) | 0.001 | Baseline uPCR | 1.0 (0.99–1.0) | 0.26 | 0.99 (0.99–1.00) | 0.15 | Interstitial fibrosis | 1.7 (0.4–6.7) | 0.46 | 0.34 (0.09–1.24) | 0.10 | % crescents | 3.0 (0.1–68.2) | 0.49 | 0.83 (0.08–8.37) | 0.87 | % sclerosed glomeruli | 0.5 (0.0–14.6) | 0.69 | 0.99 (0.07–12.99) | 0.99 |
|
|
IVCYC: intravenous cyclophosphamide, MMF: mycophenolate mofetil, eGFR: estimated glomerular rate; uPCR: urine protein-creatinine ratio.
|